Preparation and pharmacokinetics of 11C labeled stavudine (d4T)

Nuclear Medicine and Biology

Volumn 31, Issue 5, 2004, Pages 613-621

  Livni, Eli ^a,b   Berker, Mark ^a,b   Hillier, Shawn ^a,b   Waller, Stephen C ^d   Ogan, Marc D ^d   Discordia, Robert P ^d   Rienhart, J Kent ^d   Rubin, Robert H ^a,b,c   Fischman, Alan J ^a,b,c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^d BRISTOL MYERS SQUIBB   (United States)

Author keywords

AIDS; d4T; HIV; Pharmacokinetics; Radiolabeling; Stavudine

Indexed keywords

5' O (2 TETRAHYDROPYRANYL) 5 BROMO 2',3' DIDEHYDRO 3' DEOXYTHYMIDINE; RADIOPHARMACEUTICAL AGENT; STAVUDINE; STAVUDINE C 11; THYMIDINE DERIVATIVE; UNCLASSIFIED DRUG; CARBON; DIAGNOSTIC AGENT;

ADRENAL GLAND; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE; BRAIN; DRUG ACCUMULATION; DRUG DISTRIBUTION; DRUG ISOLATION; DRUG PURIFICATION; DRUG PURITY; DRUG SYNTHESIS; GASTROINTESTINAL TRACT; HEART; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISOTOPE LABELING; KIDNEY; LIVER; LUNG; MALE; METHYLATION; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; RADIATION DETECTION; RADIOACTIVITY; RAT; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SKELETAL MUSCLE; SPLEEN; STOMACH; TESTIS; TISSUE DISTRIBUTION; ANIMAL; ANTIBODY SPECIFICITY; CHEMISTRY; COMPARATIVE STUDY; METABOLIC CLEARANCE RATE; METHODOLOGY; SPRAGUE DAWLEY RAT; SYNTHESIS;

ANIMALS; CARBON RADIOISOTOPES; ISOTOPE LABELING; MALE; METABOLIC CLEARANCE RATE; ORGAN SPECIFICITY; RADIOPHARMACEUTICALS; RATS; RATS, SPRAGUE-DAWLEY; STAVUDINE; TISSUE DISTRIBUTION;

EID: 3042583644     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2003.11.006     Document Type: Article

References (33)

1. Spruance S.L., Pavia A.T., Mellors J.W., Murphy R., Gathe J., Stool E., Jemsek J.G., Dellamonica P., Cross A., Dunkle L., Gathe J. Clinical efficacy of monotherapy with stavudine compared with zidovudine in HIV-infected, zidovudine-experienced patients. A randomized, double-blind, controlled trial. Bristol-Myers Squibb Stavudine/019 Study Group. Ann Intern Med. 126:1997;355-363
2. Foudraine N.A., de Jong J.J., Jan Weverling G., van Benthem B.H., Maas J., Keet I.P., Jurriaans S., Roos M.T., Vandermeulen K., de Wolf F., Lange J.M. An open randomized controlled trial of zidovudine plus lamivudine versus stavudine plus lamivudine. AIDS. 12:1998;1513-1519
3. Kline M.W., Van Dyke R.B., Lindsey J.C., Gwynne M., Culnane M., McKinney R.E., Nichols S., Mitchell W.G., Yogev R., Hutcheon N., McKinney R.E. A randomized comparative trial of stavudine (d4T) versus zidovudine (ZDV, AZT) in children with human immunodeficiency virus infection. AIDS Clinical Trials Group 240 Team. Pediatrics. 101:1998;214-220
4. Clumeck N. Stavudine plus a non-thymidine nucleoside reverse transcriptase inhibitor as a backbone for highly active antiretroviral therappy. Antivir Ther 1998;(suppl 4):39-43
5. August E.M., Birks E.M., Prusoff W.H. 3′-Deoxythymidin-2′-ene permeation of lymphocyte H9 cells by non-facilitated diffusion. Mol Pharmacol. 39:1991;2246-2249
6. Ho H.-T., Hitchcock M.J.M. Cellular pharmacology of 2′, 3′-dideoxy-2′3′- didehyrothymidine, a nuclceoside analog active against human immunodeficiency virus. Antimicrob Agents Chemother. 33:1989;844-849
7. Dyatkina N., Minassian S., Kukhanova M., Krayevsky A., von Janta-Lipinsky M., Chidgeavadze Z., Beabealashvilli R. Properties of 2′, 3′-dideoxy-2′, 3′-dehyrothymidine 5′-triphosphate in terminating DNA synthesis catalyzed by several different DNA polymerases. FEBS Lett. 219:1987;151-155
8. Ono K., Nakane H., Herdewijn P., Balzarini J., De Clercq E. Differential inhibitory effects of several pyrimidine 2′, 3′-dideoxynucleoside 5′-triphosphates on the activities of reverse transcriptase and various cellular DNA polymerases. Mol Pharmacol. 35:1989;578-583
9. Martin J.L., Brown C.E., Matthews-Davis N., Reardon J.E. Effects of antiviral nucleoside analogs on human DNA polymerases and mitochondrial DNA synthesis. Antimicrob Agents Chemother. 38:1994;2743-2749
10. Skowron G. Biologic effects and safety of stavudine; overview of phase I and II clinical trials. J Infect Dis. 171:1995;S113-S117
11. Browne M.J., Mayer K.H., Chafee S.B., Dudley M.N., Posner M.R., Steinberg S.M., Graham K.K., Geletko S.M., Zinner S.H., Denman S.L. 2′-3′ Didehydro- 3′-deoxythymidine (d4T) in patients with AIDS or AIDS-related complex a phase I trial. J Infect Dis. 167:1993;21-29
12. Stavudine Investigator Brochure; Bristol-Myers Squibb Pharmaceutical Research Institute; 3 June, 1999
13. Yang Z., Brundage R.C., Barbhaiya R.H., Sawchuk R.J. Microdialysis studies of the distribution of stavudine into the central nervous system in the freely-moving rat. Pharm Res. 14:1997;865-872
14. Straube E., Kuhlmann B.K., Weimann M.W., Hoetelman R.H., Von Wussow P. Stavudine penetrates the blood-brain barrier. Int Conf AIDS. 12:1998;84. (abstract 12354)
15. Brady K., Aldrich J., Broston R., MacGregor R.R. Stavudine entry into cerebrospinal fluid of HIV-infected subjects after single and multiple doses. Int Conf AIDS. 12:1998;84. (abstract 12355)
16. Haworth S.J., Christofalo B., Anderson R.D., Dunkle L.M. A single-dose study to assess the penetration of stavudine into human cerebrospinal fluid in adults. J Acquir Immune Defic Syndr Hum Retrovirol. 17:1998;235-238
17. Duncan D.B. Multiple range tests and multiple F-tests. Biometrics. 11:1955;1-42
18. 18F-labeled fluconazole and positron emission tomography studies in rabbits. Int J Nucl Med Biol Part B. 19:1992;191-199
19. 18F-labeled fleroxacin. Int J Nucl Med Biol Part B. 20:1993;81-87
20. 11C dapoxetine HCl, a serotonin re-uptake inhibitor Biodistribution and preliminary PET imaging in the monkey. Nucl Med Biol. 21:1994;669-675
21. 18F-labeled fluconazole in normal human subjects studied with positron emission tomography. Antimicrob Agents Chemother. 37:1993;1270-1277
22. 18F] fleroxacin in normal human subjects studied with positron emission tomography. Antimicrob Agents Chemother. 37:1993;2144-2152
23. Stavudine Investigator Brochure; Bristol-Myers Squibb Pharmaceutical Research Institute; 3 June, 1999
24. Inoue T., Tsushita K., Itoh T., Ogura M., Hotta T., Saneyoshi M., Yoshida S., Saitoh H., Tomoda Y., Nagai Y. In vitro bone marrow toxicity of nucleoside analogs against human immunodeficiency virus. Antimicrob Agents Chemother. 33:1989;576-579
25. Schreiber S.L., Ikemoto N. Synthesis of chemically reactive analogs of AZT and their biological evaluation against HIV. Tetrahedron Lett. 29:1988;3211-3214
26. Balzarini J., Van Aerschot A., Herdewijn P., De Clercq E. 5-Chloro-substituted derivatives of 2′, 3′-didehydro-2′, 3′-dideoxyuridine, 5′-fluoro-2′, 3′dideoxyuridine and 3′-azido-2′, 3′-dideoxyuridine as anti-HIV agents. Biochem Pharmacol. 38:1989;869-874
27. Baba M., Pauwels R., Herdewijn P., De Clercq E., Desmyter J., Vandeputte M. Both 2′, 3′-didexythymidine and its 2′, 3′-unsaturated derivative (2′, 3′-dideoxythymidinene) are potent and selective inhibitors of human immunodeficiency virus in vitro. Biochem Biophys Res Commun. 142:1987;128-134
28. Hamamoto Y., Nakashima H., Matsui T., Matsuada A., Ueda T., Yamamoto N. Inhibitory effect of 2′, 3′-didehydro-2′, 3′- dideoxynucleosides on infectivity, cytopathic effects, and replication of human immunodeficiency virus. Antimicrob Agents Chemother. 31:1987;907-910
29. Balzarini J., Kang G.J., Dalal M., Herdewijn P., De Clercq E., Broder S., Johns D.G. The anti-HTLV-III (anti-HIV) and cytotoxic activity of 2′, 3′-didehydro-2′, 3′-dideoxyribonucleosides a comparison with their parental 2′, 3′-dideoxyribonucleosides. Mol Pharm. 32:1987;162-167
30. Herdewijn P., Balzarini J., DeClercq E., Pauwels R., Baba M., Broder S., Vanderhaeghe H. 3′-substituted 2′, 3′-dideoxynucleoside analogs as potential anti-HIV (HTLV-III/LAV) agents. J Med Chem. 30:1987;1270-1278
31. Mansuri M.M., Starrett J.E., Ghazzouli I., Hitchcock M.J., Sterzycki R.Z., Brankovan V., Lin T.S., August E.M., Prusoff W.H., Sommadossi J.P., Starrett J.E. 1-(2, 3-Dideoxy-D-glycero- pent-2-enofuranosyl) thymidine. A highly potent and selective anti-HIV agent. J Med Chem. 32:1989;461-466
32. Lin T.S., Schinazi R.F., Prusoff W.H. Potent and selective in vitro activity of 3′-deoxythymidine-2′-ene (3′-deoxy-2, 3′-didehydrothymidine) against human immunodeficiency virus. Biochem Pharmacol. 36:1987;2713-2718
33. Cretton E.M., Zhou Z., Kidd L.B., McClure H.M., Kaul S., Hitchcock M.J.M., Sommadossi J.P. In vitro and in vivo disposition and metabolism of 3′-deoxy-2′, 3′didehydrothymidine. Antimicrob Agents Chemother. 37:1993;1816-1825